Podcast


Presenter: Adrienne J Lindblad BSP ACPR PharmD James McCormack BSc (Pharm) Pharm D Mike Allan MD

Podcast: BS Medicine Episode #451 Osteoarthritis – All the Evidence for all the Treatments – PART III
0:00

In episode 451, Mike and James invite Adrienne to talk about how we put all the osteoarthritis evidence into a simplified decision guide. We talk about how we produce these decision guides and also give tips and suggestions around how to use the evidence with patients. At the conclusion of this activity, participants will be…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here



CFPCLearn Logo

Listening to the Podcast can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in



Latest Podcasts

BS Medicine Episode #610: Vitamin D and Mortality – Don’t bet your life on it!

In episode 610, Jamie and James chat with Jennifer Young about yet another Vitamin D Tools for Practice. We look at what happens to mortality, CVD and cancer when Vitamin…
Listen 0.5 credits available

Pharmascope Épisode 115: Ostéoporose: solidifier la prise en charge – partie 3

Un nouvel épisode du Pharmascope est maintenant disponible! Dans de ce 115ème épisode, Sébastien, Nicolas et Isabelle terminent leur série d’épisodes sur l’ostéoporose. Dans cette troisième et dernière partie, on…
Listen 0.5 credits available

Pharmascope Épisode 114: Ostéoporose: solidifier la prise en charge – partie 2

Un premier épisode du Pharmascope enregistré devant public est maintenant disponible! En direct de Jonquière, Sébastien, Nicolas et Isabelle continuent leur série d’épisodes sur l’ostéoporose. Dans cette deuxième partie, on…
Listen 0.5 credits available

Presenter(s):

Adrienne J Lindblad BSP ACPR PharmD James McCormack BSc (Pharm) Pharm D Mike Allan MD

This content is certified for MainPro+ Credits, log in to access


Presenter(s):

  • Adrienne J Lindblad BSP ACPR PharmD
  • James McCormack BSc (Pharm) Pharm D
  • Mike Allan MD

Spearkers do not have any conflicts of interest to declare.